Across TCGA pan-cancer cohorts, CARF mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CARF data layer compared with 25 for mass-spec protein and 7 for mutation status.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CARF mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CARF expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.
LSCC, LUAD, and GBM are the cancer types where CARF mass-spec protein most reproducibly stratifies survival.